Skip to main content

Advertisement

SpringerLink
Log in

Anaemia

FIND-CKD: intravenous iron in predialysis CKD

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

A new study has advanced our understanding of iron management in chronic kidney disease (CKD) by comparing oral iron to high-dose and low-dose intravenous ferric carboxymaltose (FCM) in patients with predialysis CKD. Intravenous FCM treatment to achieve a higher serum ferritin target improved patient haemoglobin levels and reduced initiation of other anaemia treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fishbane, S., Pollack, S., Feldman, H. I. & Joffe, M. M. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004 Clin. J. Am. Soc. Nephrol. 4, 57–61 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Stancu, S. et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am. J. Kidney Dis. 55, 639–647 (2010).

    Article  CAS  PubMed  Google Scholar 

  3. Vadasz, D., Ries, V. & Oertel, W. H. Intravenous iron sucrose for restless legs syndrome in pregnant women with low serum ferritin. Sleep Med. 11, 1214–1216 (2013).

    Article  Google Scholar 

  4. Macdougall, I. C. et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfu201.

  5. Pfeffer, M. A. et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).

    Article  PubMed  Google Scholar 

  6. Singh, A. K. et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).

    Article  CAS  PubMed  Google Scholar 

  7. Manns, B. J. & Tonelli, M. The new FDA labeling for ESA—implications for patients and providers. Clin. J. Am. Soc. Nephrol. 7, 348–353 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Agarwal, R., Vasavada, N., Sachs, N. G. & Chase, S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 65, 2279–2289 (2004).

    Article  CAS  PubMed  Google Scholar 

  9. Sengoelge, G. et al. Impairment of transendothelial leukocyte migration by iron complexes. J. Am. Soc. Nephrol. 14, 2639–2644 (2003).

    Article  CAS  PubMed  Google Scholar 

  10. The European Medicines agency EU clinical trials register [online] (2014).

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Hofstra North Shore-Long Island Jewish School of Medicine, 100 Community Drive, Great Neck, 11021, NY, USA

    Steven Fishbane & Azzour D. Hazzan

Authors
  1. Steven Fishbane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Azzour D. Hazzan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Fishbane.

Ethics declarations

Competing interests

S.F. is a consultant for Keryx Biopharmaceuticals Inc. A.D.H. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fishbane, S., Hazzan, A. FIND-CKD: intravenous iron in predialysis CKD. Nat Rev Nephrol 10, 488–489 (2014). https://doi.org/10.1038/nrneph.2014.139

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2014.139

  • Springer Nature Limited

Search

Navigation